ARS Pharmaceuticals shares jumped Monday after the company inked a deal to commercialize its allergic reaction nasal spray internationally.

Common decongestants may soon be pulled from shelves. The Food and Drug Administration (FDA) announced Wednesday its proposal ...

ALK-Abelló has acquired rights to Neffy adrenaline nasal spray in Europe and Canada, amongst other countries, from ARS ...

The U.S. Food and Drug Administration is taking the first step to remove an ingredient in non-prescription cold medicines ...

News reporter for Orlando Weekly, with a focus on state and local government, workers' rights, and housing issues. Previously ...

A Danish company is spending $145 million upfront for certain rights to the first-ever needle-free adrenaline nasal spray for severe allergic reactions, unlocking sales potential of more than $400 ...

ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak sales of around $400 million in anaphylaxis treatment.

Although ARS Pharmaceuticals’ approval for its epinephrine nasal spray came later than expected, the company ultimately received a thumbs up from the FDA in August and is now moving fast to expand ...

Phenylephrine is included in many cold and flu products, but a scientific panel last year found that it doesn't really do its ...

The agreement grants ALK exclusive global rights to the neffy ® adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China. The deal delivers on key ...

Phenylephrine is both the most common decongestant on pharmacy shelves, and arguably the worst at its job. Last year, the FDA ...

On Thursday, the FDA proposed removing oral phenylephrine from the list of approved active ingredients for over-the-counter ...